Nole's Mole Hole

[nole92]

POSC - Down to $.05 and $45M market cap. Forgiveness of debt helped them break even for the quarter. I plan to keep them on watch with the introduction of Cardio-Assist scheduled for commercial deployment during the first quarter of 2011.

Positron Announces Third Quarter 2010 Financial Results Revenue Increased by Over 400%; Debt Levels Reduced by 90%)

INDIANAPOLIS, Nov 17, 2010 (GlobeNewswire via COMTEX) -- Positron Corporation
(OTCBB:POSC), a leading molecular imaging company specializing in the field of
nuclear cardiology, today announced financial results for the third quarter
ended September 30, 2010.

Highlights of the third quarter included:

-- An increase in revenue of 439% from the prior year period;

-- Sales of 13 Attrius(R) PET systems since 2010 product launch;

-- A posting of net income in the current quarter over the prior year

period's net loss; and,

-- A 90% reduction in debt levels since year-end (excluding customer

deposits/unearned revenue).

During the quarter Positron made significant strides in expanding its position
and visibility in the marketplace, while simultaneously continuing to fortify
its balance sheet. Since quarter-end debt levels were further reduced, leaving
the Company effectively debt-free. The sales ramp-up and market awareness
campaigns have also been in full force; as of November 15th, Positron had sales
orders of 12 Attrius(R) PET systems.

"We continue to execute our strategy of being the leader in cardiac PET, which
we believe will yield positive revenue and earnings growth patterns over the
long-term," said Patrick G. Rooney, chief executive officer of Positron.

The Company noted that as of the third quarter it received customer deposits,
not yet recognized as revenue, totaling $2.3 million. The Company expects to
recognize the deposits and balance of payments by customers associated with
these sales orders as revenue during the first half of 2011.

During the three months ended September 30, 2010, the Company also reported an
increase in operating expenses to $2.5 million from $1.1 million in the prior
year period. Over the past 12 months the Company has expended substantial
resources on the research and development of its two major business segments,
including the development of Positron's Nuclear Cardio-Assist(TM) and its
radiopharmaceutical manufacturing facility, and sales and marketing efforts for
the Attrius(R) Cardiac PET system. As a result of investments made, Positron
expects a significant increase in sales of the Attrius(R) Cardiac PET system and
related service contracts, as well as sales of radiopharmaceuticals through the
Company's dose dispensing systems, and the manufacturing of
radiopharmaceuticals. The Company expects that these developments will have a
positive impact on revenue and net margins.